Literature DB >> 21321139

Activity of and development of resistance to corallopyronin A, an inhibitor of RNA polymerase.

Katherine Mariner1, Martin McPhillie, Rachel Trowbridge, Catriona Smith, Alex J O'Neill, Colin W G Fishwick, Ian Chopra.   

Abstract

We explored the properties of corallopyronin A (CorA), a poorly characterized inhibitor of bacterial RNA polymerase (RNAP). It displayed a 50% inhibitory concentration of 0.73 μM against RNAP, compared with 11.5 nM for rifampin. The antibacterial activity of CorA was also inferior to rifampin, and resistant mutants of Staphylococcus aureus were easily selected. The mutations conferring resistance resided in the rpoB and rpoC subunits of RNAP. We conclude that CorA is not a promising antibacterial drug candidate.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21321139      PMCID： PMC3088244          DOI： 10.1128/AAC.01742-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid.

Authors:  A J O'Neill; J M Bostock; A Morais Moita; I Chopra
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  ExPASy: The proteomics server for in-depth protein knowledge and analysis.

Authors:  Elisabeth Gasteiger; Alexandre Gattiker; Christine Hoogland; Ivan Ivanyi; Ron D Appel; Amos Bairoch
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

3.  Stress-based identification and classification of antibacterial agents: second-generation Escherichia coli reporter strains and optimization of detection.

Authors:  Elyse Shapiro; François Baneyx
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 4.  Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques.

Authors:  Alex J O'Neill; Ian Chopra
Journal:  Expert Opin Investig Drugs       Date:  2004-08       Impact factor: 6.206

5.  Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.

Authors:  A J O'Neill; T Huovinen; C W G Fishwick; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1991-06       Impact factor: 5.790

7.  Further characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studies.

Authors:  Katherine R Mariner; Nicola Ooi; Deborah Roebuck; Alex J O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

8.  The corallopyronins, new inhibitors of bacterial RNA synthesis from Myxobacteria.

Authors:  H Irschik; R Jansen; G Höfle; K Gerth; H Reichenbach
Journal:  J Antibiot (Tokyo)       Date:  1985-02       Impact factor: 2.649

9.  The myxopyronins, new inhibitors of bacterial RNA synthesis from Myxococcus fulvus (Myxobacterales).

Authors:  H Irschik; K Gerth; G Höfle; W Kohl; H Reichenbach
Journal:  J Antibiot (Tokyo)       Date:  1983-12       Impact factor: 2.649

10.  The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra
Journal:  J Antimicrob Chemother       Date:  2003-12-04       Impact factor: 5.790
View more
  6 in total

1.  Influence of DNA template choice on transcription and inhibition of Escherichia coli RNA polymerase.

Authors:  Joerg Haupenthal; Kristina Hüsecken; Matthias Negri; Christine K Maurer; Rolf W Hartmann
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Novel rapidly diversifiable antimicrobial RNA polymerase switch region inhibitors with confirmed mode of action in Haemophilus influenzae.

Authors:  Ed T Buurman; Melinda A Foulk; Ning Gao; Valerie A Laganas; David C McKinney; Demetri T Moustakas; Jonathan A Rose; Adam B Shapiro; Paul R Fleming
Journal:  J Bacteriol       Date:  2012-07-27       Impact factor: 3.490

3.  Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.

Authors:  Aashish Srivastava; David Degen; Yon W Ebright; Richard H Ebright
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 4.  New target for inhibition of bacterial RNA polymerase: 'switch region'.

Authors:  Aashish Srivastava; Meliza Talaue; Shuang Liu; David Degen; Richard Y Ebright; Elena Sineva; Anirban Chakraborty; Sergey Y Druzhinin; Sujoy Chatterjee; Jayanta Mukhopadhyay; Yon W Ebright; Alex Zozula; Juan Shen; Sonali Sengupta; Rui Rong Niedfeldt; Cai Xin; Takushi Kaneko; Herbert Irschik; Rolf Jansen; Stefano Donadio; Nancy Connell; Richard H Ebright
Journal:  Curr Opin Microbiol       Date:  2011-08-19       Impact factor: 7.934

5.  Structural basis of head to head polyketide fusion by CorB.

Authors:  Georg Zocher; Joachim Vilstrup; Daniel Heine; Asis Hallab; Emilie Goralski; Christian Hertweck; Mark Stahl; Till F Schäberle; Thilo Stehle
Journal:  Chem Sci       Date:  2015-08-06       Impact factor: 9.825

6.  The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus.

Authors:  Jan Balansky; Kenneth Pfarr; Christiane Szekat; Stefan Kehraus; Tilman Aden; Miriam Grosse; Rolf Jansen; Thomas Hesterkamp; Andrea Schiefer; Gabriele M König; Marc Stadler; Achim Hoerauf; Gabriele Bierbaum
Journal:  Antibiotics (Basel)       Date:  2022-07-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.